These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 8823578)

  • 1. Update on the pathophysiology and management of gastro-oesophageal reflux disease: the role of prokinetic therapy.
    Tytgat GN; Janssens J; Reynolds JC; Wienbeck M
    Eur J Gastroenterol Hepatol; 1996 Jun; 8(6):603-11. PubMed ID: 8823578
    [No Abstract]   [Full Text] [Related]  

  • 2. [Are prokinetic drugs still indicated for gastro-oesophageal reflux in children?].
    Dupont C; Benhamou PH
    Arch Pediatr; 2004 Jun; 11(6):671-3. PubMed ID: 15158877
    [No Abstract]   [Full Text] [Related]  

  • 3. The role of delayed gastric emptying and impaired oesophageal body motility.
    Penagini R; Bravi I
    Best Pract Res Clin Gastroenterol; 2010 Dec; 24(6):831-45. PubMed ID: 21126697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Addition of prokinetic therapy to a PPI in reflux diseases.
    Hsu YC; Lin HJ
    Aliment Pharmacol Ther; 2011 Apr; 33(8):983-4; author reply 984-5. PubMed ID: 21434953
    [No Abstract]   [Full Text] [Related]  

  • 5. Progress with novel pharmacological strategies for gastro-oesophageal reflux disease.
    Tonini M; De Giorgio R; De Ponti F
    Drugs; 2004; 64(4):347-61. PubMed ID: 14969571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Morning or evening dosage of omeprazole for gastro-oesophageal reflux disease?
    Savarino V; Mela GS; Vigneri S
    Aliment Pharmacol Ther; 1996 Jun; 10(3):447-8. PubMed ID: 8791976
    [No Abstract]   [Full Text] [Related]  

  • 7. Emerging drugs for gastro-oesophageal reflux disease.
    Wurm P; De Caestecker J
    Expert Opin Emerg Drugs; 2005 May; 10(2):457-71. PubMed ID: 15934879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review article: the clinical relevance of transient lower oesophageal sphincter relaxations in gastro-oesophageal reflux disease.
    Kessing BF; Conchillo JM; Bredenoord AJ; Smout AJ; Masclee AA
    Aliment Pharmacol Ther; 2011 Mar; 33(6):650-61. PubMed ID: 21219371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of mosapride, a novel prokinetic, on acid reflux variables in patients with gastro-oesophageal reflux disease.
    Ruth M; Hamelin B; Röhss K; Lundell L
    Aliment Pharmacol Ther; 1998 Jan; 12(1):35-40. PubMed ID: 9692698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prokinetics in the treatment of gastro-oesophageal reflux disease. International symposium. Paris, France, 5 September 1996.
    Heading RC; Baldi F; Holloway RH; Janssens J; Jian R; McCallum RW; Richter JE; Scarpignato C; Sontag SJ; Wienbeck M
    Eur J Gastroenterol Hepatol; 1998 Jan; 10(1):87-93. PubMed ID: 9512959
    [No Abstract]   [Full Text] [Related]  

  • 11. [Cisapride treatment for children with gastro-esophageal reflux].
    Kneepkens CM; Hoekstra JH; Vandenplas Y
    Ned Tijdschr Geneeskd; 1999 Oct; 143(42):2091-4. PubMed ID: 10560558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of baclofen on gastro-oesophageal reflux, lower oesophageal sphincter function and reflux symptoms in patients with reflux disease.
    van Herwaarden MA; Samsom M; Rydholm H; Smout AJ
    Aliment Pharmacol Ther; 2002 Sep; 16(9):1655-62. PubMed ID: 12197845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gastroesophageal reflux and prokinetic agents.
    Hammer D
    Neonatal Netw; 2005; 24(2):51-8; quiz 59-62. PubMed ID: 15835479
    [No Abstract]   [Full Text] [Related]  

  • 14. The effects of tegaserod (HTF 919) on oesophageal acid exposure in gastro-oesophageal reflux disease.
    Kahrilas PJ; Quigley EM; Castell DO; Spechler SJ
    Aliment Pharmacol Ther; 2000 Nov; 14(11):1503-9. PubMed ID: 11069322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of cisapride on acid gastro-oesophageal reflux during treatment with caffeine.
    Kentrup H; Baisch HJ; Kusenbach G; Heimann G; Skopnik H
    Biol Neonate; 2000 Feb; 77(2):92-5. PubMed ID: 10657685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update on drugs for gastro-oesophageal reflux disease.
    Keady S
    Arch Dis Child Educ Pract Ed; 2007 Aug; 92(4):ep114-8. PubMed ID: 17644666
    [No Abstract]   [Full Text] [Related]  

  • 17. Management of reflux-related symptoms.
    Dutta U; Moayyedi P
    Best Pract Res Clin Gastroenterol; 2013 Jun; 27(3):387-400. PubMed ID: 23998977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of ABT-229, a motilin agonist, on acid reflux, oesophageal motility and gastric emptying in patients with gastro-oesophageal reflux disease.
    Netzer P; Schmitt B; Inauen W
    Aliment Pharmacol Ther; 2002 Aug; 16(8):1481-90. PubMed ID: 12182748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of cisapride in maintaining symptomatic remission in patients with gastro-oesophageal reflux disease.
    Hatlebakk JG; Johnsson F; Vilien M; Carling L; Wetterhus S; Thøgersen T
    Scand J Gastroenterol; 1997 Nov; 32(11):1100-6. PubMed ID: 9399390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Internal medicine therapy in reflux disease].
    Flad J
    Praxis (Bern 1994); 1996 Nov; 85(45):1432-8. PubMed ID: 8975352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.